Patent Portfolio
Decision Sciences holds foundational intellectual property protecting the world's first spatial agent-based model of the AGE-RAGE-sRAGE feedback loop in hepatic fibrosis — covering simulation architecture, irreversibility prediction, biomarker strategies, and novel numerical methods.
Provisional Applications
Filed Patents
U.S. Prov. App. No. 64/100,396
Provisional — ActiveFiled
June 27, 2026
Core Simulation Architecture & Clinical Applications
Systems and Methods for Computational Prediction of Hepatic Fibrosis Progression, Irreversibility Detection, and Treatment Management
Covers the core simulation architecture, irreversibility prediction algorithms, sRAGE-based biomarker strategies, and stage-specific treatment guidance systems.
Key Coverage Areas
U.S. Prov. App. No. 64/101,014
Provisional — ActiveFiled
June 29, 2026
Foundational Numerical Methods
Method for Resolution-Invariant Computational Simulation of Biological Tissue Using Variational Lagrangian Discretization
Covers the novel numerical methods enabling resolution-invariant tissue simulation — a foundational advance for scaling digital-twin applications across tissue types and disease states.
Key Coverage Areas
IP Strategy
What We Protect
Our patent strategy covers both the clinical application layer — how the simulation predicts irreversibility and guides treatment — and the foundational computational layer that makes high-fidelity tissue simulation tractable. Together, these patents protect the full stack from numerical methods to clinical decision support.
Simulation Architecture
The spatial, GPU-accelerated 3D agent-based model structure and its 14-subsystem coupling methodology.
Irreversibility Prediction
Algorithms for detecting stage-dependent irreversibility thresholds as emergent properties — without explicit stage-gating rules.
sRAGE Biomarker Strategy
Methods for using sRAGE trajectory divergence as a clinically measurable indicator of the reversibility transition point.
Numerical Methods
Variational Lagrangian discretization enabling resolution-invariant simulation — scalable across tissue types and disease states.
Partnership Opportunities
Licensing & Co-Development
We are actively seeking partners for licensing, co-development, and clinical validation. Our technology is ready for integration into pharmaceutical development pipelines, clinical research platforms, and digital health applications.
Pharmaceutical Licensing
License the simulation platform to support RAGE/AGE-targeted drug development — identify optimal patient populations, predict responder profiles, and design stage-stratified clinical trials.
Clinical Research Co-Development
Partner with clinical researchers to validate sRAGE biomarker predictions against longitudinal patient cohorts — generating the clinical evidence base for regulatory submissions.
Digital Health Integration
Integrate the digital-twin simulation engine into precision medicine platforms, EHR-connected decision support tools, or patient monitoring systems.
Ready to explore a partnership?
All licensing inquiries are handled directly by Wayne Eskridge, Founder.